Neuroendocrine prostate cancer (NEPC) may be rising in prevalence as patients with advanced prostate cancer potentially develop resistance to contemporary anti-androgen treatment through a neuroendocrine phenotype. | Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma